DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare ... ( PRINCETON N.J. Sept. 3 /-...)

DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference

Date:9/3/2009

PRINCETON, N.J., Sept. 3 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that Christopher J. Schaber, Ph.D., President and Chief Executive Officer, will present at the Rodman & Renshaw 11th Annual Global Investor Healthcare Conference. Dr. Schaber is scheduled to present at 4:55 PM on Thursday, September 10, 2009 in the Spellman Salon of the New York Palace Hotel, New York. The presentation will be webcast live and may be accessed by visiting http://www.wsw.com/webcast/rrshq15/dorb.ob.

Dr. Schaber will provide updates on DOR's pipeline, including its lead product candidate orBec(R) which is soon to begin a confirmatory Phase 3 clinical trial for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

A replay of Dr. Schaber's webcast will be available on DOR BioPharma's new website (www.dorbiopharma.com) for approximately 30 days following the presentation.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD and a Phase 1/2 clin
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
2. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
5. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
6. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
7. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
8. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
9. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

Post Your Comments:

(Date:11/19/2009)... InSound is honored by latest award fo... Newark, CA (PRWEB) November 16, 2009 -- Popu...visible” hearing aid from InSound Medical a ...rd in the Health category. ...ed to reside deep in the hearing canal for up to f...

(Date:11/18/2009)...y personnel need to be able to find explosive mate...em. To aid such searches, the National Institute o...om the Department of Homeland Security, has develo...eference Material (SRM) 2905, Trace Particulate Ex...ay methods, the SRM will be helpful in calibrating...

(Date:11/18/2009)... Vernier,s experience in data analysis combined wi...am kits and curricula provide state-of-the...BEAVERTON, Ore., Nov. 18 Vernier S...l science interfaces, sensors, and software and Bi...urer and distributor of life science research and ...

(Date:11/18/2009)...SISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM ...fe sciences product development company that ident...g cancer-related products at various stages of dev...uating nimotuzumab were presented today in a poste... Cancer Therapeutics conference in Boston, Massach...

Breaking Biology Technology:Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2 Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3 New NIST trace explosives standard slated for homeland security duty 2 Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2 YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2 YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3

... and understanding in the field of, bioabsorbabl...8, 2008, ORANGEBURG, S.C., Aug. 22 Zeus, Inc., a... it will be hosting an informative,and cutting-edg...Polymers,as Biomaterials." Presented by Dr. Bruce ...e insight into the development of synthetic,bioabs...

...Consumer Product Safety Commission (CPSC) to carry...products such as children,s jewelry and toy trains...y of complex, high-tech products made using nanote...e Project on Emerging Nanotechnologies (PEN). , ...e CPSC are being used in the Olympic Games in Beij...

...(Nasdaq: TELK ) announced today that the lead com...or program met a significant development milestone...se function is required for,cancer cell division, ...(VEGFR) plays a key role in tumor blood vessel for...o support tumor growth. Telik,s lead,compounds pre...

Other Biology Technology:Zeus Webinar: Bioabsorbable Polymers as Biomaterials 2 Consumer Product Safety Commission not ready for nanotech 2 Consumer Product Safety Commission not ready for nanotech 3 Telik's Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone 2

Zeus Webinar: Bioabsorbable Polymers as Biomaterials Consumer Product Safety Commission not ready for nanotech Telik's Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone

(Date:11/20/2009)..., Researchers are invited to contribute their abs...(IOF WCO ECCEO10), the largest global meeting dev...itis research and patient care. The Congress will ... Beginning today, abstracts can be submitted onlin...ission deadline is February 4, 2010. , IOF and E...

(Date:11/20/2009)..., North Grafton, Mass., November 19, 2009 The es...ne industry may be at risk of developing respirato..., according to a questionnaire study undertaken ea...ty,s Cummings School of Veterinary Medicine. , T...e barn workersfound that 50 percent of individuals...

(Date:11/20/2009)..., Brussel, November 19th 2009 - Bacteria possess ...harming the building blocks of the cell. This is t...es Joris Messens of VIB, a life sciences research ...rije Universiteit Brussel. The scientists made thi... bacterium Escherichia coli . By means of this mo...

[0] Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 [0] Barn personnel experience higher-than-average rates of respiratory symptoms [0] Biologists discover bacterial defense mechanism against aggressive oxygen

... from the National Institute of Oceanography and t...expedition on research vessel Polarstern. The coop...n how ocean ecosystems function. But it has dampen... sequester significant amounts of carbon dioxide (...ch the scientists reached Punta Arenas, Chile, tog...

...iracid has finally been identified after a search ...p can cause severe poisoning in human consumers o...ssues. The scientific periodical European Journal...44/1: p. 63-79) that a tiny algal species, the din...Researchers from the Alfred Wegener Institute for ...

... in over-the-counter skin creams. Recent results f... that it is associated with major environmental ri...day use form a mixture in the ocean that has a dir...isms", says scientist Tobias Porsbring. , When Eu...y often do so for one chemical at a time. Recent r...

Other Biology News:Lohafex provides new insights on plankton ecology 2 Lohafex provides new insights on plankton ecology 3 Lohafex provides new insights on plankton ecology 4 Cause of mussel poisoning identified 2 Drug used to treat skin conditions is a marine pollutant 2

Lohafex provides new insights on plankton ecology Cause of mussel poisoning identified Drug used to treat skin conditions is a marine pollutant

Wheat Germ Phosphatase, Acid, Unconjugated from Sigma-Aldrich

Shrimp Phosphatase, Alkaline, Unconjugated from Sigma-Aldrich

Adenosine 5'-triphosphate (ATP) Luminescence Assay Kit from Thermo Scientific

...refrigerated cold traps offers a choice of tempera... solvents or high volatility solvents. Ideal to pu...ugal evaporators. Also used for maintaining vapor-...electron microscopes. Can be used as mini point of...

Biology Products:

Wheat Germ Phosphatase, Acid, Unconjugated from Sigma-Aldrich Shrimp Phosphatase, Alkaline, Unconjugated from Sigma-Aldrich Adenosine 5'-triphosphate (ATP) Luminescence Assay Kit from Thermo Scientific RCT 60 -55C, 4 Liter Refrigerated Cold Trap from Thermo Scientific

DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare ...( PRINCETON N.J. Sept. 3 /-...)